To boost or not? Serum anti-COVID IgG in double vaccinated MBBS students: a cross-sectional study

Nitu Sharma; Prince Jain

doi:10.18203/2320-6012.ijrms20242210

Authors

Nitu Sharma Dept. of Bio-Chemistry, Amaltas Institute of Medical Sciences, Dewas – 455001, Madhya Pradesh, India
Prince Jain Dept. of Bio-Chemistry, Amaltas Institute of Medical Sciences, Dewas – 455001, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242210

Keywords:

WHO, Severe Acute Respiratory Syndrome Corona virus 2, Sero-positive, Prevalence, Booster doses, COVID-19 Pandemic

Abstract

Background: Aim of the study was to estimate the prevalence of sero-positivity i.e. serum anti-covid IgG >1.4 AU/ml in MBBS students of our Institute.

Methods: This study was carried out on 75 MBBS students of our institute (10% of 750 MBBS students of Amaltas institute of Medical Sciences Dewas M.P. India) during period of August 2022 to November 2022. All serum anti-covid IgG titres above 1.4 AU/ml were considered sero-positive and the prevalence of sero-positivity was calculated. MBBS students were asked to fill out a questionnaire regarding their clinical history of testing positive for covid, exposure to COVID-19 patients, their covid appropriate behavior, etc. After obtaining informed consent, 4 ml venous blood samples were collected for determining serum anti-covid IgG titre on Chemiluminescence analyzer. 75 MBBS students divided into 2 groups – those who completed between 6-9 months and those who have completed more than 9 months after the 2nd dose of vaccine. The mean serum anti-covid IgG titre was compared.

Results: The prevalence of sero-positivity was 94.66% calculated in MBBS students of our institute. The total antibody sero-positivity was higher in males (98.11%) than in females (86.36). The duration after 2nd dose of vaccine; over the time 6-9 months serum anti-covid IgG titre significantly high but after more than 9 months serum anti covid IgG titre significantly decline (p<0.001) and significant correlation was found between duration after 2nd dose of vaccine and serum anti-covid IgG titres (p<0.001).

Conclusions: This study; strongly recommended the need for booster doses for long-duration protection against COVID-19 re-infection and its emerging new variants.

Metrics

Metrics Loading ...

References

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-286.

Andrews MA, Areekal B, Rajesh KR. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res. 2020;151(5):490-492.

CoWIN Dashboard. Accessed October 26, 2022.

Erice A, Varillas-Delgado D, Caballero C. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28(1):139.

Achiron A, Gurevich M, Falb R, Dreyer-Alster S, Sonis P, Mandel M. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2021;27(9):1349.

Doria-Rose N, Suthar MS, Makowski M, O’Connell S, Flach B, Ledgerwood JE, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19. N Engl J Med. 2021;384(23):2259-61.

Wu M, Wall EC, Carr EJ. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet Lond Engl. 2022;399(10326):715-7.

Sugawara N, Yasui-Furukori N, Fukushima A, Shimoda K. Attitudes of Medical Students toward COVID-19 Vaccination: Who Is Willing to Receive a Third Dose of the Vaccine? 2021;9(11):1295.

High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcalá, Spain: Contributing Factors - PMC. Int J Gen Med. 2021; 14:7017-24.

Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019-PMC. Clin Transl Immunology. 2020;9(5):e1136.

Nakano Y, Kurano M, Morita Y. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11(1):2776.

Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland-PMC. PLoS One. 2021;16(4):e0249550.

Marklund E, Leach S, Axelsson H. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PloS One. 2020;15(10):1104.

Anti-SARS-CoV-2 Seropositivity Among Medical Students in Copenhagen - PMC. Open Forum Infect Dis. 2021;8(8):273.

Javed W, Abidi SHB, Baqar JB. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific sease symptoms. BMC Infect Dis. 2022;22(1):481.